KR830007596A - 3,4-비스-치환된 1,2,5-옥스디아졸 2-옥사이드의 제조방법 - Google Patents

3,4-비스-치환된 1,2,5-옥스디아졸 2-옥사이드의 제조방법 Download PDF

Info

Publication number
KR830007596A
KR830007596A KR1019810004968A KR810004968A KR830007596A KR 830007596 A KR830007596 A KR 830007596A KR 1019810004968 A KR1019810004968 A KR 1019810004968A KR 810004968 A KR810004968 A KR 810004968A KR 830007596 A KR830007596 A KR 830007596A
Authority
KR
South Korea
Prior art keywords
process according
nhr
alkali metal
formula
integer
Prior art date
Application number
KR1019810004968A
Other languages
English (en)
Other versions
KR880000543B1 (ko
Inventor
쉐나핀게르 칼
바이에를르 루디
모길레프 안톤
본 헬무트
주스트 멜리타
아 마르토라나 피에로
니츠 롤프-에베르하르트
Original Assignee
쿠르트 발세르, 한스-게오르그 우르바하
카셀라 아크티엔 게젤샤프트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 쿠르트 발세르, 한스-게오르그 우르바하, 카셀라 아크티엔 게젤샤프트 filed Critical 쿠르트 발세르, 한스-게오르그 우르바하
Publication of KR830007596A publication Critical patent/KR830007596A/ko
Application granted granted Critical
Publication of KR880000543B1 publication Critical patent/KR880000543B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/08—1,2,5-Oxadiazoles; Hydrogenated 1,2,5-oxadiazoles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Materials For Photolithography (AREA)
  • Macromonomer-Based Addition Polymer (AREA)

Abstract

내용 없음

Description

3,4-비스-치환된 1,2,5-옥스디아졸 2-옥사이드의 제조방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (10)

  1. 일반식(Ⅱ)의 히드록사모일클로라이드를 0° 내지 50℃에서 용매 또는 분산제에 도입시켜, HCl을 탈이시키고 이합체화시킴을 특징으로 하여 일반식(Ⅰ)의 3, 4-비스-치환된 1, 2, 5-옥스디아졸 2-옥사이드 및 그의 약물학적으로 무독한 산부가염을 제조하는 방법.
    상기식에서, R은 -NHR1, -NR2R3, -NHR4OR2, -NHR5COR6또는이고, R1은 탄소원자 1 내지 6의 알킬 또는 탄소원자 4 내지 7의 시클로알킬이며, R2및 R3는 탄소원자 1 내지 4의 알킬이고, R4는 -CnH2n- 인 알킬렌라디칼이며, n은 2,3 또는 4의 정수이고 R5는 일반식 -CmH2m-인 알킬렌 라디칼이며 m은 1,2 또는 3의 정수이고 R6는 -OR2, -NHR1, -NR2R3또는-NH2이고, X는 (CH2)p-, -(CH2)2- O-(CH2)2-또는이며 p는 4,5 또는 6의 정수이다.
  2. 제 1항에 있어서, 일반식(Ⅱ)의 히드록사모일클로라이드를 10 내지 25℃에서 용매 또는 분산제에 도입시킴을 특징으로 하는 방법.
  3. 제 1항 또는 제 2항에 있어서, 염기를 바람직하게는 동몰량 가함을 특징으로하는 방법.
  4. 제 1항 내지 제3항중의 어느 하나에 있어서, 라디칼 R이 -NH 그룹을 함유함을 특징으로하는 방법.
  5. 제 1항 내지 제4항중의 어느 하나에 있어서, R4가 -(CH2)2- 또는 -(CH2)3를 나타냄을 특징으로하는 방법.
  6. 제 1항 내지 제4항중의 어느 하나에 있어서, R5가 -CH2-또는 (CH2)2를 나타냄을 특징으로하는 방법.
  7. 제 1항 내지 제4항중의 어느 하나에 있어서, R2가 메틸 또는 에틸을 나타냄을 특징으로 하는 방법.
  8. 제 1항 내지 제7항중의 어느 하나에 있어서, 사용한 용매가 디메틸포름아미드, 디메틸설폭사이드, N-메틸피롤리돈, 저급알콜, 디에틸에테르, 물 또는 이들 용매의 혼합물인 것을 특징으로 하는 방법.
  9. 제 1항 내지 제9항중의 어느 하나에 있어서, 부가한 염기가 2금 또는 3급아민, 알칼리금속 히이드록사이드, 알칼리금속탄산염, 알칼리금속중탄산염 또는 알칼리금속 아세테이트인 것을 특징으로 하는 방법.
  10. 제 1항 내지 제9항중의 어느 하나에 있어서, 염기를 서서히 또는 소량씩 부가함을 특징으로 하는 방법.
    ※참고사항:최초출원 내용에 의하여 공개하는 것임.
KR1019810004968A 1980-12-18 1981-12-17 3,4-비스-치환된 1,2,5-옥스디아졸 2-옥사이드의 제조방법 KR880000543B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19803047730 DE3047730A1 (de) 1980-12-18 1980-12-18 3,4-bis-substituierte 1,2,5-oxdiazol-2-oxide, verfahren zu ihrer herstellung, ihre verwendung und sie enthaltende pharmazeutische zubereitungen
DE3047730.6 1980-12-18
DEP304773006 1980-12-18

Publications (2)

Publication Number Publication Date
KR830007596A true KR830007596A (ko) 1983-11-04
KR880000543B1 KR880000543B1 (ko) 1988-04-13

Family

ID=6119497

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019810004968A KR880000543B1 (ko) 1980-12-18 1981-12-17 3,4-비스-치환된 1,2,5-옥스디아졸 2-옥사이드의 제조방법

Country Status (28)

Country Link
US (1) US4356178A (ko)
EP (1) EP0054872B1 (ko)
JP (1) JPS57123173A (ko)
KR (1) KR880000543B1 (ko)
AR (1) AR227697A1 (ko)
AT (1) ATE10094T1 (ko)
AU (1) AU542529B2 (ko)
CA (1) CA1157019A (ko)
CS (1) CS219863B2 (ko)
DD (1) DD201897A5 (ko)
DE (2) DE3047730A1 (ko)
DK (1) DK150597C (ko)
ES (1) ES508086A0 (ko)
FI (1) FI813666L (ko)
GR (1) GR81375B (ko)
HK (1) HK51385A (ko)
HU (1) HU183751B (ko)
IE (1) IE52034B1 (ko)
IL (1) IL64563A (ko)
NO (1) NO814045L (ko)
NZ (1) NZ199272A (ko)
PH (1) PH18051A (ko)
PL (1) PL128564B1 (ko)
PT (1) PT74129B (ko)
RO (1) RO84099B (ko)
SG (1) SG21285G (ko)
SU (1) SU1093246A3 (ko)
ZA (1) ZA818726B (ko)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4507485A (en) * 1984-01-23 1985-03-26 Bristol-Myers Company 3,4-Disubstituted-1,2,5-oxadiazoles having histamine H2 -receptor antagonist activity
DE4217794A1 (de) * 1992-05-29 1993-12-02 Cassella Ag Phenylfuroxane
DE4218582A1 (de) * 1992-06-05 1993-12-09 Cassella Ag Pyridyl-1,2,5-oxadiazol-carbonamid-2-oxide
DE4218979A1 (de) * 1992-06-10 1993-12-16 Cassella Ag Pyrimidofuroxane
DE4220264A1 (de) * 1992-06-20 1993-12-23 Cassella Ag Phenyl-1,2,5-oxadiazol-carbonamid-2-oxide
DE4223800A1 (de) * 1992-07-20 1994-01-27 Cassella Farbwerke Mainkur Ag Verwendung von 1.2.5-Oxadiazol-2-oxiden zur Behandlung erektiler Dysfunktionen
DE4307105A1 (de) * 1993-03-06 1994-09-08 Cassella Ag Hydroxymethylfurazancarbonsäurederivate
US5460669A (en) * 1993-06-28 1995-10-24 Thiokol Corporation 3-nitramino-4-nitrofurazan and salts thereof
DE4401150A1 (de) * 1994-01-17 1995-07-20 Cassella Ag Furazancarbonsäurederivate
JP2008543863A (ja) 2005-06-15 2008-12-04 ハイドラ バイオサイエンシズ インコーポレイテッド 精子の運動亢進のモジュレーター及びその利用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4089867A (en) * 1976-11-11 1978-05-16 Texaco Inc. Preparation of diacylfurazan oxides

Also Published As

Publication number Publication date
US4356178A (en) 1982-10-26
SG21285G (en) 1985-09-13
IE52034B1 (en) 1987-05-27
ES8300101A1 (es) 1982-10-01
CA1157019A (en) 1983-11-15
RO84099A (ro) 1984-05-12
DK150597C (da) 1987-10-26
AU7855881A (en) 1982-06-24
DE3167001D1 (en) 1984-12-06
IL64563A0 (en) 1982-03-31
RO84099B (ro) 1984-06-30
AR227697A1 (es) 1982-11-30
FI813666L (fi) 1982-06-19
GR81375B (ko) 1984-12-11
NZ199272A (en) 1984-03-16
DD201897A5 (de) 1983-08-17
AU542529B2 (en) 1985-02-21
JPH0223551B2 (ko) 1990-05-24
DK150597B (da) 1987-04-06
PT74129B (de) 1983-05-16
PT74129A (de) 1982-01-01
EP0054872A1 (de) 1982-06-30
DE3047730A1 (de) 1982-07-15
ES508086A0 (es) 1982-10-01
ATE10094T1 (de) 1984-11-15
HU183751B (en) 1984-05-28
HK51385A (en) 1985-07-12
PH18051A (en) 1985-03-13
ZA818726B (en) 1982-11-24
EP0054872B1 (de) 1984-10-31
DK533881A (da) 1982-06-19
SU1093246A3 (ru) 1984-05-15
IE812976L (en) 1982-06-18
IL64563A (en) 1985-02-28
PL128564B1 (en) 1984-02-29
NO814045L (no) 1982-06-21
CS219863B2 (en) 1983-03-25
KR880000543B1 (ko) 1988-04-13
JPS57123173A (en) 1982-07-31
PL234257A1 (ko) 1982-08-02

Similar Documents

Publication Publication Date Title
DK290180A (da) Fremgangsmaade til fremstilling af substituerede piperidiner eller pyrrolidiner
KR830007596A (ko) 3,4-비스-치환된 1,2,5-옥스디아졸 2-옥사이드의 제조방법
FI792849A (fi) Immunomodulatorer och antivirala aemnen
KR850004500A (ko) 2-플루오로-17β-에스트라디올의 제조방법
ATE26439T1 (de) Ethersulfonate und ihre herstellung.
AU527592B2 (en) 3,20-dioxo-4,9-diene-21-hydroxyl steroid derivatives
KR860004088A (ko) 피플루 오로 알킬 비닐 중합체의 제조방법
AR241467A1 (es) Aminas de poliester oxalquiladas y procedimiento para su preparacion.
DK496189A (da) Fluorsubstituerede benzenderivater
FI820087L (fi) Ljuskaenslig blandning baserad pao o-naftokinondiazider och avenna framstaellt kopiermaterial
KR830005110A (ko) 플루오렌 유도체의 제조방법
ES431707A1 (es) Un procedimiento de sulfonacion de alcoholes secundarios etoxilados.
SE7909751L (sv) 4,1-bensoxazepiner och tia-analoger derav
KR850004470A (ko) 유기 화합물의 제조방법
ES453997A1 (es) Procedimiento para la preparacion de acetatos de eteraminas secundarias.
KR830006285A (ko) 벤조퀴놀리진의 제조방법
SE7907188L (sv) Sett att framstella hydroximetyl-4(5)-legre alkyl-5(4)-imidazoler och deras syraadditionssalter
SE7905060L (sv) Nya 1-pyrrol- och 1-pyrrolidin-karboxylsyraderivat och sett for framstellning derav
JPS5553251A (en) Polymerizable amino acid compound
KR890009951A (ko) Si.Si'- 디오가닐-N- 알킬- 테트라클로로- 디실라잔 및 이의 제조방법
ES274908A1 (es) Procedimiento para la preparaciën de nuevos derivados de iminodibencilo
KR830010081A (ko) 2-아미노-5,6-디히드로 피리미딘-4-온 유도체의 제조방법
KR880012530A (ko) 2-아미노-4-아실아미노페닐 에테르의 제조방법
JPS5517357A (en) Preparation of aqueous blocked isocyanate
GB2017145A (en) Motor Fuel Compositions Containing Asparagine Derivatives